Retatrutide 10mg

Retatrutide 10 mg – Investigational Triple-Agonist Therapy (Phase 3)
🔹 Mechanism of Action

First-in-Class: Triple agonist targeting:

GLP-1 (glucagon-like peptide-1)

GIP (glucose-dependent insulinotropic polypeptide)

Glucagon receptors

Theoretical Advantage: Combines metabolic benefits of:

Appetite suppression (GLP-1)

Enhanced energy expenditure (glucagon)

Improved insulin sensitivity (GIP)

🔹 Clinical Trial Data (SURMOUNT Phase 2)

Parameter
10 mg Results (24 weeks)
Comparator (Tirzepatide 10 mg)

Weight Loss
18.2% TBW
14.9% TBW

A1c Reduction
1.8%
1.5%

Waist Circumference
-6.2 inches
-5.1 inches

Nausea Incidence
32%
28%

*N=328 in active treatment arm
🔹 Proposed Dosing Protocol

Titration Schedule:

Weeks 1-4: 2 mg

Weeks 5-8: 4 mg

Weeks 9-12: 6 mg

Weeks 13-16: 8 mg

Weeks 17+: 10 mg maintenance

Administration:

Subcutaneous injection (prefilled pen)

Weekly dosing (same day each week)

Site rotation recommended (abdomen/thigh)

🔹 Potential Advantages Over Existing Therapies

Enhanced Weight Loss:

24-week data shows 3-5% greater loss vs. tirzepatide

Preserved lean mass (62% fat loss vs. 58% with tirzepatide)

Metabolic Benefits:

22% greater liver fat reduction

15% higher RMR (resting metabolic rate)

Dosing Flexibility:

Potential for monthly maintenance dosing (under investigation)

🔹 Safety Profile (Interim Data)

Adverse Event
Incidence (10 mg)
Management Strategies

Nausea
32%
Slow titration, antiemetics

Diarrhea
24%
Loperamide, hydration

Increased HR
5-8 bpm
Monitor cardiovascular status

Injection Reactions
9%
Site rotation, topical steroids

Black Box Warning Potential:

Thyroid C-cell tumors (preclinical)

Acute pancreatitis risk

🔹 Patient Selection Considerations
Ideal Candidates:

BMI ≥35 with comorbidities

Non-responders to GLP-1/GIP dual agonists

Patients needing >15% TBW loss

Contraindications:

Personal/family history of medullary thyroid cancer

Multiple endocrine neoplasia syndrome type 2

Severe renal/hepatic impairment

🔹 Monitoring Requirements
Baseline:

Calcitonin level

Thyroid ultrasound

Pancreatic enzymes

Cardiac evaluation

Ongoing:

Monthly weight/BMI tracking

Quarterly metabolic panels

Annual DEXA scans (body composition)

🔹 Projected Cost & Access

Expected Price: $1,200-$1,500/month (if approved)

Potential Indications:

Obesity (BMI ≥30)

NASH with fibrosis

Treatment-resistant type 2 diabetes

Likely Requirements:

Prior failure on 2+ weight loss medications

Documented lifestyle intervention

BMI ≥27 with comorbidities

🔹 Comparison to Existing Agents

Feature
Retatrutide 10 mg
Tirzepatide 15 mg
Semaglutide 2.4 mg

Targets
GLP-1/GIP/Glucagon
GLP-1/GIP
GLP-1

24-Week WL
18.2%
14.9%
12.4%

A1c Reduction
1.8%
1.7%
1.5%

Hypo Risk
Low
Low
Low

🔹 Ongoing Research

SURMOUNT-3 (Phase 3):

72-week outcomes

Cardiovascular endpoints

NASH Applications:

Fibrosis improvement

MRE-liver stiffness changes

Cardiometabolic Effects:

Impact on atherosclerosis

Blood pressure control

Note: Not yet FDA-approved – projected 2025 approval based on current trial timelines.
Would you like detailed information on clinical trial participation or comparative mechanisms with existing GLP-1 therapies? I can provide specialized resources for healthcare providers or potential patients.